期刊文献+

血浆纤溶酶原激活物抑制剂-1在年青冠心病患者中的表达 被引量:3

下载PDF
导出
摘要 目的研究血浆纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor type-1,PAI-1)分子在年青冠心病患者中的表达以及与冠心病病情的关系。方法入选患者按照年龄分为年青组和老年组,检测所有入选患者的PAI-1分子含量,年青组患者病情稳定后一月复查PAI-1含量。结果年青组患者血清PAI-1为(44.27±2.8)mol/L,老年组PAI-1的血清含量为(39.14±3.60)mol/L,两组含量有统计学意义(P<0.05);一月后年青组复查PAI-1的血清含量为(33.85±2.4)mol/L,与发病急性期PAI-1分子含量相比,含量有统计学意义(P<0.05)。结论 PAI-1是年青患者冠心病的独立预测因素之一,且PAI-1含量的高低与冠心病的时期有明显相关性。对于接受冠心病长期规范治疗的患者,PAI-1的血清含量与冠心病的病情相关性还需要进一步研究。
出处 《中西医结合心脑血管病杂志》 2012年第5期611-612,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献8

  • 1Mlynarska A,Waszyrowski T,Kasprzak JD.Plasminogen activator inhibitor-1 (PAI-1):Pathogenetic role in coronary disease[J].Kardiol Pol,2007,65(9):1109-1114.
  • 2Aleksic N,Wang YW,Ahn C,et al.Assessment of coronary heart disease risk by combined analysis of coagulation factors[J].Atherosclerosis,2008,198(2):294-300.
  • 3Rott D,Leibowitz D,Finci-Yeheskel Z,et al.The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction[J].Cardiology,2009,112(1):56-59.
  • 4应淑琴,徐耕,单江.冠心病介入治疗前后患者血浆P-选择素、血栓调节蛋白、纤溶酶原激活剂抑制剂-1的变化[J].中国介入心脏病学杂志,2001,9(3):135-137. 被引量:3
  • 5Martinelli N,Trabetti E,Pinotti M,et al.Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis[J].Plos One,2008,3(2):e1523.
  • 6Corsetti JP,Ryan D,Moss AJ,et al.Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients[J].Arterioscler Thromb Vasc Biol,2008,28(3):548-554.
  • 7Garg N,Fay WP.Plasminogen activator inhibitor-1 and restenosis[J].Curr Drug Targets,2007,8(9):1003-1006.
  • 8Sakai T,Inoue S,Takei M,et al.Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome:Immunohistochemical analysis[J].Thromb Res,2011,127(5):443-449.

二级参考文献6

  • 1[1]Lindsay CD, Michael PS, Linda JB, et al. Characterization of GMP-40 (P-selectin) as a circulating plasma protein. J Exp Med, 1992,175:1147-1150.
  • 2[2]Esmon CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem, 1989,264:4743-4752.
  • 3[3]Warzok F, Steiner M, Blann AD, et al. Immediate and late effects of coronary angiography on soluble endothelial cell markers and P-selectin in patients with and without coronary artery disease. Blood Coagul Fibrinolysis, 1999,10:381-387.
  • 4[4]Tomoda H, Aoki N. Plasma soluble p-selectin in acute myocardial infarction: effects of coronary recanalization therapy. Angiology, 1998,49:807-813.
  • 5[5]Inoue T, Hoshi K, Fujito T, et al. Early detection of platelet activation after coronary angioplasty. Coron Artery Dis, 1996,7:529-534.
  • 6[6]Kamikura Y, Wada H, Yamada A, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol, 1997,55:183-187.

共引文献2

同被引文献24

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部